Market Overview

Jefferies Reiterates Buy Rating, $34 PT on Partnership with Alnylam Pharmaceuticals

Related MDCO
The Medicines Company Announces BARDA Exercises Next Option on Contract for Support of the Development of CARBAVANCE® (meropenem/RPX7009) for Drug-Resistant Gram-Negative Pathogens
Mid-Afternoon Market Update: NASDAQ Down 1.3%; Medicines Company Shares Gain Following Announcement Of Positive ALN-PCSsc Study Results

In a report published Monday, Jefferies reiterated its Buy rating and $34.00 price target on The Medicines Company (NASDAQ: MDCO).

Jefferies noted, “This morning, MDCO and Alnylam Pharmaceuticals (ALNY, $24.24, NC) announced they have formed a strategic partnership to develop a RNAi-based therapeutic program for the treatment of hypercholesterolemia. Included in this program is ALN-PCS02, an intravenously administered RNAi therapeutic targeting PCSK9, a protein that circulates in the plasma and plays a major role in regulating LDL-C levels by binding LDL-receptors on hepatocytes, inducing internalization and degradation of the receptor. RNAi represents a different mechanistic approach to targeting PCSK9 by silencing the gene that synthesizes the protein, v. REGN727 (REGN, $172.88, Hold) and AMG145 (AMGN, $86.30, Buy) that are antibodies that block the interaction b/w PCSK9 and the LDL-R. MDCO/ALNY believes its approach may offer advantages from the antibody approach: 1) it could modulate both intracellular and extracellular PCSK9 for a more complete effect, and 2) it could allow a more consistent pharmacologic effect given the high variability of PCSK9 levels across pts. However, these theoretical advantages remain to be borne out in clinical studies.”

The Medicines Company closed on Friday at $30.53.

Latest Ratings for MDCO

Aug 2015RBC CapitalMaintainsOutperform
Aug 2015JefferiesMaintainsBuy
Aug 2015JefferiesUpgradesHoldBuy

View More Analyst Ratings for MDCO
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Reiteration Analyst Ratings


Related Articles (ALNY + MDCO)

Get Benzinga's Newsletters